Schizophrenia can be a severe and disabling illness. This study examines a promising novel treatment for schizophrenia and provide critical information about its use in people who do not respond to other treatment. Sodium benzoate is a common food additive, but some initial clinical studies suggest it may also be effective in alleviating some symptoms experienced by people with schizophrenia.

The exact cause of schizophrenia is unknown. The disorder is characterised by thoughts or experiences that seem out of touch with reality, disorganised speech or behaviour and decreased participation in daily activities. While a few studies have shown a reduction in schizophrenia symptoms with the use of sodium benzoate, the dose required to treat the disorder has not been determined, and the mechanism of action of this compound is unknown. This ongoing study is recruiting patients to commence on sodium benzoate or placebo. Thirty-three out of 52 patients have been recruited, and both blood testing and a standard interview to measure the severity of their symptoms have been performed.

At the end of this project, participants’ interviews and blood samples will be analysed to determine whether sodium benzoate is effective in reducing schizophrenia symptoms and the required dose to achieve such results. Moreover, Prof Scott's project is expected to provide the mechanism of action for treating schizophrenia. Promising novel treatments can offer critical care for people who do not respond to other treatments.